X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BIOCON - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BIOCON GLENMARK PHARMA/
BIOCON
 
P/E (TTM) x 16.6 39.1 42.3% View Chart
P/BV x 2.9 6.2 47.6% View Chart
Dividend Yield % 0.4 0.2 190.8%  

Financials

 GLENMARK PHARMA   BIOCON
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
BIOCON
Mar-18
GLENMARK PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs9301,188 78.3%   
Low Rs517305 169.6%   
Sales per share (Unadj.) Rs322.668.7 469.4%  
Earnings per share (Unadj.) Rs28.57.6 377.3%  
Cash flow per share (Unadj.) Rs39.214.0 280.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.1 206.3%  
Book value per share (Unadj.) Rs183.086.3 211.9%  
Shares outstanding (eoy) m282.17600.00 47.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.210.9 20.7%   
Avg P/E ratio x25.498.9 25.7%  
P/CF ratio (eoy) x18.553.4 34.6%  
Price / Book Value ratio x4.08.6 45.7%  
Dividend payout %7.013.2 53.0%   
Avg Mkt Cap Rs m204,206447,900 45.6%   
No. of employees `00013.76.1 223.1%   
Total wages/salary Rs m18,7189,311 201.0%   
Avg. sales/employee Rs Th6,636.86,705.8 99.0%   
Avg. wages/employee Rs Th1,364.71,514.2 90.1%   
Avg. net profit/employee Rs Th586.1736.9 79.5%   
INCOME DATA
Net Sales Rs m91,03141,234 220.8%  
Other income Rs m9142,062 44.3%   
Total revenues Rs m91,94543,296 212.4%   
Gross profit Rs m16,1548,291 194.8%  
Depreciation Rs m3,0193,851 78.4%   
Interest Rs m2,856615 464.3%   
Profit before tax Rs m11,1935,887 190.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1551,569 201.1%   
Profit after tax Rs m8,0394,531 177.4%  
Gross profit margin %17.720.1 88.3%  
Effective tax rate %28.226.7 105.7%   
Net profit margin %8.811.0 80.4%  
BALANCE SHEET DATA
Current assets Rs m69,88741,486 168.5%   
Current liabilities Rs m32,87921,413 153.5%   
Net working cap to sales %40.748.7 83.5%  
Current ratio x2.11.9 109.7%  
Inventory Days Days8164 127.3%  
Debtors Days Days9394 99.3%  
Net fixed assets Rs m28,89250,661 57.0%   
Share capital Rs m2823,000 9.4%   
"Free" reserves Rs m51,35348,808 105.2%   
Net worth Rs m51,63551,808 99.7%   
Long term debt Rs m41,41817,898 231.4%   
Total assets Rs m125,95499,897 126.1%  
Interest coverage x4.910.6 46.5%   
Debt to equity ratio x0.80.3 232.2%  
Sales to assets ratio x0.70.4 175.1%   
Return on assets %8.65.2 167.9%  
Return on equity %15.68.7 178.0%  
Return on capital %15.19.6 156.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31712,058 301.2%   
Fx outflow Rs m9,7207,348 132.3%   
Net fx Rs m26,5984,710 564.7%   
CASH FLOW
From Operations Rs m16,4816,621 248.9%  
From Investments Rs m-10,133-6,840 148.1%  
From Financial Activity Rs m-4,685-2,397 195.5%  
Net Cashflow Rs m1,770-2,612 -67.8%  

Share Holding

Indian Promoters % 48.3 40.4 119.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 6.9 8.4 82.1%  
FIIs % 34.4 10.7 321.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   56,727 109,995 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 24, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS